- Home
- ASPN vs CELC Comparison
ASPN vs CELC Comparison
Compare ASPN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPN
- CELC
- Stock Information
- Founded
- ASPN 2001
- CELC 2011
- Country
- ASPN United States
- CELC United States
- Employees
- ASPN N/A
- CELC N/A
- Industry
- ASPN RETAIL: Building Materials
- CELC Medical Specialities
- Sector
- ASPN Consumer Discretionary
- CELC Health Care
- Exchange
- ASPN Nasdaq
- CELC Nasdaq
- Market Cap
- ASPN 486.5M
- CELC 440.0M
- IPO Year
- ASPN 2014
- CELC 2017
- Fundamental
- Price
- ASPN $6.14
- CELC $12.61
- Analyst Decision
- ASPN Strong Buy
- CELC Strong Buy
- Analyst Count
- ASPN 10
- CELC 6
- Target Price
- ASPN $21.78
- CELC $30.67
- AVG Volume (30 Days)
- ASPN 1.4M
- CELC 195.0K
- Earning Date
- ASPN 08-06-2025
- CELC 08-13-2025
- Dividend Yield
- ASPN N/A
- CELC N/A
- EPS Growth
- ASPN N/A
- CELC N/A
- EPS
- ASPN N/A
- CELC N/A
- Revenue
- ASPN $436,921,000.00
- CELC N/A
- Revenue This Year
- ASPN N/A
- CELC N/A
- Revenue Next Year
- ASPN $24.31
- CELC N/A
- P/E Ratio
- ASPN N/A
- CELC N/A
- Revenue Growth
- ASPN 51.90
- CELC N/A
- 52 Week Low
- ASPN $4.16
- CELC $7.58
- 52 Week High
- ASPN $33.15
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- ASPN 52.44
- CELC 66.25
- Support Level
- ASPN $5.72
- CELC $11.52
- Resistance Level
- ASPN $6.21
- CELC $12.54
- Average True Range (ATR)
- ASPN 0.32
- CELC 0.65
- MACD
- ASPN -0.01
- CELC 0.07
- Stochastic Oscillator
- ASPN 55.56
- CELC 89.68
About ASPN Aspen Aerogels Inc.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.